MedImmune to Stimulate Maryland Economy By Building A New Biomanufacturing Facility
Unlike many of its big pharma competitors which are shuttering US manufacturing facilities, MedImmune, the biologics division of London-based pharmaceutical giant AstraZeneca, Friday, opened a second bioproduction site in Frederick, MD.
The site which will employ 250 or more workers was constructed to manufacture MedImmune’s products including Synagis, a monoclonal antibody-based treatment against respiratory syncytial virus infections in high risk children.
The acquisition of MedImmune by AstraZeneca three years ago signaled the company’s commitment to increasing it biologics offerings in its historically-traditional small molecule drug pipeline. While the reasons for the company’s decision to build a second plant in Frederick aren’t entirely clear, it is great news for Maryland’s expanding commitment to biotechnology. There are approximately 350 biotechnology companies doing business in the state.
The addition of over 250 biotechnology and manufacturing jobs is certain to stimulate the Maryland economy; something that other big pharma companies have been reluctant to do. Investing in biomanufacturing is something that can help the US reinvigorate its moribund manufacturing sector. And, whether you believe it or not, the US is still second-to-none when it comes to manufacturing biologics and other biotechnology products.
Hat tip to MedImmune for the bold move!
Similar Posts:
- Business Update: Biogen Idec and Samsung Biologics Announce Formation of Biosimilar Joint Venture
- And The Worst Biotech CEO of 2011 Is……
- Are US Immigration Laws Really Hurting Life Science Innovation?
- New Thoughts on Pharmacovigilance, Adverse Event Reporting and Social Media
- Spirit North Carolina expansion to bring 200 aviation jobs
